Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

NCT ID: NCT06310057

Last Updated: 2024-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2024-03-01

Brief Summary

The goal of this clinical trial is to assess the efficacy of tofacitinib in refractory axial spodyloarthritis (ax-SpA) with dose escalation from 10mg to 15mg. Patients will start on 10mg and then divided into 2 groups (10 and 15) at 3rd month according to major improvement criteria.

The main question[s] it aims to answer are:

• Efficacy and safety of tofacitinib in different doses
• If escalation of tofacitinib is justified if clinical criteria is not fulfilled at 10mg

Detailed Description

Axial spondyloarthritis (ax-SpA) is a major cause of chronic low back pain in the young. It causes significant disability and impairs quality of life. Management of (ax-SpA) includes physical therapy along with NSAIDs, followed by TNFi or IL-17i or JAKi in refractory ax-SpA. In Bangladesh, TNFi and IL-17i are expensive, whereas Tofacitinib (JAKi) is affordable and widely used in Bangladesh. However, recent study shows that a significant number of patients, 39.4% do not meet criteria for ASDAS CRP clinically important criteria and only 26% meets the criteria for ASDAS major improvement to tofacitinib 10mg daily. 102 patients of refractory ax-SpA meeting the enrollment criteria will be taken and put on 10mg tofacitinib. Those who fail to attain ASDAS CRP major improvement criteria at 12 weeks will be put on 15mg tofacitinib and both the groups will be compared at week 24 in a dose escalation study.

No studies have been done on 15mg tofacitinib for ax-SpA, such a study will provide us ground for escalation of tofacitinib. Regarding safety issues, FDA has warned against the use of 20mg tofacitinib but not for 15mg. Baseline characteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. The study will take place in Rheumatology outdoor, BSMMU and Modern One Stop Arthritis Care and Research Centre, Dhaka from July 2022- April 2024. Patient's socio-demographic and clinical data will be taken in a semi-structured questionnaire. At every follow up detailed history, thorough physical examination and investigations will be done to evaluate the efficacy and adverse effects. Patients will be assessed for response, ASDAS-CRP, ASDAS-ESR, ASAS-20, BASFI, BASDAI, BASMI, ASQoL, SF-36, MASES and VAS will be noted. CBC, CRP, S. creatinine and S. ALT will be done during follow up.

Conditions

Axial Spondyloarthritis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tofacitinib 10mg

All patient that fulfill the inclusion ans exclusion criteria will start at 10mg tofacitinib.

Group Type: EXPERIMENTAL

Tofacitinib

Intervention Type: DRUG

Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.

Tofacitinib 15 mg

At 3rd month, patients that do not fulfill the ASDAS major improvement criteria will get 15mg tofacitinib.

Group Type: EXPERIMENTAL

Tofacitinib

Intervention Type: DRUG

Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.

Interventions

Tofacitinib

Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years

2. Patient fulfill the ASAS classification criteria for ax-SpA

3. Patient fulfill the definition of refractory axial ax-SpA

4. Patients with ASDAS-CRP>2.1

Exclusion Criteria

1. Patient currently taking or had prior treatment with bDMARD or tsDMARD (including JAK inhibitor)

2. Patient with any active or history of any chronic or recurrent or serious or opportunistic infection/sepsis (including tuberculosis)

3. Hemoglobin (Hb) < 9 g/dl

4. White blood cell count < 4000, Neutrophil count < 1000, Platelet count < 100000/mm3

5. Live vaccines within 3 months prior to the first dose

6. GFR less than 50 mL/min

7. Alanine aminotransaminase (ALT) more than 2 times of ULN

8. Pregnant or breast feeding females of child-bearing potential not using highly effective contraception

9. Evidence or history of malignancy

10. New York Heart Association Class III and IV congestive heart failure

11. Any lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Incepta Pharmaceuticals Ltd

INDUSTRY

Sponsor Role: collaborator

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

Sponsor Role: lead

Responsible Party

Abdul Mahin Tazbir

MD Resident

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Bangabandhu Sheikh Mujib Medical University

Dhaka, , Bangladesh

Countries

Bangladesh

Other Identifiers

4139

Identifier Type: -

Identifier Source: org_study_id